Precision Cannabinoids: a Complex Plant for Complex Pediatric Patients.
C4T is thrilled to host the second ICRS Pediatric Special Interest Group pre-conference meeting
C4T will be hosting a special interest group meeting on cannabinoid therapeutics for children at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium on the Cannabinoids on June 30, 2024 in Salamanca, Spain.
The theme of our meeting this year is Precision Cannabinoids: a Complex Plant for Complex Pediatric Patients.
For more information about ICRS, including program, travel, and accommodations, please visit their website here.
Speakers
-
Associate Professor David (Dedi) Meiri heads the Laboratory of Cancer Biology and Cannabinoid Research at the Faculty of Biology in the Technion. Dr. Meiri comes from a highly diverse scientific background in biochemistry, plant biotechnology and cancer.
The research conducted in Dr. Meiri’s lab sets out to bridge the gap between herbal and modern medicine. The lab investigates the vast therapeutic potential of secondary metabolites from cannabis and other herbs, algae and psychedelic mushrooms; and reveals how these naturally occurring metabolites affect various types of cancer, inflammatory diseases and disorders of the nervous system such as epilepsy, Alzheimer’s and others. The lab consists of a highly trained team of skilled professionals and students, working in synergy to achieve the highest level of results, to better understand the complexity and diversity of cannabis and other natural components, and realize their full therapeutic potential for human health.
-
Ethan Russo, MD, is a board-certified child and adult neurologist (1987), psychopharmacologist, and Founder/CEO of CReDO Science https://credo-science.com. He is also Chief Medical Officer to Andira Pharmaceuticals Andira – Bringing Healing to Life, Senior Medical Advisor to Canurta Home | Canurta and Medical Director of Breeder’s Best HOME - Breeder's Best - Connecting Independent Cannabis Breeders to World Markets (breedersbest.com).
He was Director of R&D for the International Cannabis and Cannabinoids Institute, 2017-19, Medical Director of PHYTECS, 2015-2017, and from 2003-2014, Senior Medical Advisor, medical monitor/study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® and Epidiolex®.
He was a clinical neurologist in Missoula, Montana for 20 years.
He has held faculty appointments as Adjunct Associate Professor, Department of Pharmaceutical Sciences, University of Montana and Clinical Assistant Professor, University of Washington School of Medicine.
He is author/editor of seven books and has published over than 60 peer-reviewed articles.
He was a 1973 graduate of the University of Pennsylvania (Psychology), University of Massachusetts Medical School (1978), and trained in pediatrics (Phoenix Hospitals Affiliated Pediatrics Program) (1978-1980) and pediatric and adult neurology at the University of Washington (1980-1983).
-
Rachel Tyndale, PhD is the Canada Research Chair in Pharmacogenomics, head of Pharmacogenetics at the Centre for Addiction and Mental Health and a Professor in the Departments of Pharmacology & Toxicology, and Psychiatry, at the University of Toronto. Dr. Tyndale’s research focuses on sources of variation between individuals in drug response in the clinical area of addictions and comorbidities. Dr. Tyndale seeks to identify and understand risk factors, and underlying mechanisms, in substance dependence and to implement approaches to personalize treatment. Her laboratory program also has a major interest in understanding how interindividual variation in drug metabolizing enzymes within the liver and brain alter drug and toxin effects. Dr. Tyndale sits on numerous scientific advisory boards, editorial boards, chaired NIH’s PharmacoGenomics Research Network (PGRN.org), and was a lead writer on the Surgeon General’s Report on Tobacco Cessation. Dr. Tyndale has supervised over 100 scientists, post-doctoral fellows and graduate students, published over 450 papers, reviews and book chapters, given over 250 invited presentations and received over 50 awards in clinical and basic pharmacology, neuroscience and genetics.
-
Dr. Lauren Kelly, is a Pharmacologist and Associate Professor in the Departments of Pharmacology and Therapeutics at the University of Manitoba. She is the Clinical Trials Director and a Scientist at the Children’s Hospital Research Institute of Manitoba and the Director at Increasing capacity for Maternal and Paediatric Clinical Trials (IMPaCT).